Bavarian Nordic beats revenue expectations, as launch of takeover bid nears

Bavarian Nordic reported stronger-than-expected Q2 revenue of 1.65 billion DKK and tightened its full-year guidance to 6.0-6.6 billion DKK, driven by robust travel health and public preparedness businesses. This performance comes as the vaccine maker is subject to a recommended 19 billion DKK (~$3 billion) takeover bid from a consortium led by Nordic Capital and Permira. However, the deal faces uncertainty as major shareholder ATP, holding a 10% stake, opposes the offer, and CEO Paul Chaplin indicated openness to potential competing bids, with the acquisition requiring over 90% shareholder acceptance.

Analysis

Bavarian Nordic demonstrated strong underlying performance, reporting second-quarter revenue of 1.65 billion Danish crowns, which significantly exceeded the analyst consensus of 1.46 billion DKK. This outperformance, driven by its travel health and public preparedness businesses, prompted management to tighten its full-year revenue guidance to a range of 6.0-6.6 billion DKK, signaling increased confidence in its operational outlook. This solid financial report provides a critical backdrop to the pending 19 billion DKK takeover offer from a consortium led by Nordic Capital and Permira. However, the deal's completion faces substantial uncertainty. A key obstacle is the stated opposition from ATP, a major shareholder with a 10% stake, which is problematic for a deal requiring over 90% shareholder acceptance. Furthermore, CEO Paul Chaplin's comment that "if there are other interested parties, they know where we are" subtly suggests the board's receptiveness to a superior proposal, positioning the current 233 crowns per share offer as a potential floor rather than a definitive ceiling.

Key Decisions for Investors

• Investors should recognize the high risk of the current takeover bid failing, given the 90% acceptance threshold and the public opposition from a 10% shareholder, making a pure M&A arbitrage strategy precarious.
• The strong Q2 earnings beat and improved guidance suggest the company's fundamental value may support the stock price independently, warranting an assessment of Bavarian Nordic's standalone valuation should the deal collapse.
• Monitor for potential competing bids, as the CEO's comments and strong operational results could attract rival suitors, creating a potential catalyst for a higher offer price.